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http://www.biomedcentral.com/1472-6823/14/65RESEARCH ARTICLE Open AccessFasting insulin sensitivity indices are not better
than routine clinical variables at predicting insulin
sensitivity among Black Africans: a clamp study in
sub-Saharan Africans
Eugene Sobngwi1,2,12*, Andre-Pascal Kengne3,4, Justin B Echouffo-Tcheugui5, Simeon Choukem6,7,
Joelle Sobngwi-Tambekou8, Eric V Balti2,9, Mark S Pearce10, Valentin Siaha2, Aissa S Mamdjokam2, Valery Effoe2,11,
Eric Lontchi-Yimagou12, Oliver T Donfack12, Barbara Atogho-Tiedeu12, Philippe Boudou13,
Jean-Francois Gautier14 and Jean-Claude Mbanya1,2Abstract
Background: We aimed to evaluate the predictive utility of common fasting insulin sensitivity indices, and
non-laboratory surrogates [BMI, waist circumference (WC) and waist-to-height ratio (WHtR)] in sub-Saharan Africans
without diabetes.
Methods: We measured fasting glucose and insulin, and glucose uptake during 80/mU/m2/min euglycemic clamp
in 87 Cameroonians (51 men) aged (SD) 34.6 (11.4) years. We derived insulin sensitivity indices including HOMA-IR,
quantitative insulin sensitivity check index (QUICKI), fasting insulin resistance index (FIRI) and glucose-to-insulin ratio
(GIR). Indices and clinical predictors were compared to clamp using correlation tests, robust linear regressions and
agreement of classification by sex-specific thirds.
Results: The mean insulin sensitivity was M = 10.5 ± 3.2 mg/kg/min. Classification across thirds of insulin sensitivity
by clamp matched with non-laboratory surrogates in 30-48% of participants, and with fasting indices in 27-51%,
with kappa statistics ranging from −0.10 to 0.26. Fasting indices correlated significantly with clamp (/r/=0.23-0.30),
with GIR performing less well than fasting insulin and HOMA-IR (both p < 0.02). BMI, WC and WHtR were equal or
superior to fasting indices (/r/=0.38-0.43). Combinations of fasting indices and clinical predictors explained 25-27%
of variation in clamp values.
Conclusion: Fasting insulin sensitivity indices are modest predictors of insulin sensitivity measured by euglycemic
clamp, and do not perform better than clinical surrogates in this population.Background
Type 2 diabetes mellitus (T2DM) and obesity, which are
both associated with insulin resistance, are increasingly
common worldwide, especially in developing countries
including sub-Saharan African (SSA) [1,2]. Furthermore,
the highest relative increases in diabetes (by 90%) pre-
valence by 2030 is projected to occur in SSA [3]. The* Correspondence: sobngwieugene@yahoo.fr
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unless otherwise stated.experienced increasing trends of T2DM and obesity over
the last two decades in SSA have revealed new chal-
lenges for diagnosis, prevention and treatment, as well
as uncovering context specific causes and promoters of
the conditions. Given the central role of insulin resis-
tance in the pathogenesis of T2DM and obesity, mea-
sures of insulin sensitivity are very important diagnostic
and research tools. The gold standard for assessing insu-
lin sensitivity is the hyperinsulinemic-euglycemic clamp,
which measures the in vivo rate of insulin-stimulated
glucose uptake [4]. However, this method is invasive,
costly, logistically challenging, technically demanding,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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not applicable in large-scale epidemiological and inter-
vention studies, especially in resource-poor settings of
SSA. Surrogate indices of insulin sensitivity that can be
used in large-scale studies have been developed [5], and
validated in several populations [5], mainly Caucasians.
However, there are suggestions that ethnicity may influ-
ence the performance of available surrogate indices of
insulin sensitivity, particularly among populations with
high prevalence of insulin resistance such as Africans [6,7].
This issue however, remains largely under-investigated and
little is known on the diagnostic utility of common insulin
sensitivity indices, and whether they even do better than
non-laboratory-based determinants of insulin sensitivity, in
SSA populations. We therefore assessed the performance
of common fasting indices of insulin sensitivity and clinical
surrogates of insulin resistance, against hyperinsulinemic-
euglycemic clamp-measured insulin sensitivity, among
non-diabetic Cameroonians adults with a wide range of in-
sulin sensitivity/resistance profile.
Methods
Study population
We recruited 87 non-diabetic volunteers of sub- Saharan
African origin (51 men and 36 women) aged 21 to 61
years, from 2006 to 2008 in Cameroon. Eligible healthy
subjects were recruited through the outpatient clinic of
the National Obesity Center of the Yaounde Central
Hospital [8]. Potential participants were screened by his-
tory, physical examination and biochemical tests. A fast-
ing plasma glucose of ≥ 126 mg/dl (7 mmol/L) indicated
diabetes [9]. Participants with serum creatinine concen-
trations >1.5 mg/dl, on medications that may impact on
energy metabolism, with human immunodeficiency virus
(HIV)-positive status, or with overt chronic liver, renal,
or thyroid disease, active coronary artery disease, and
smoking more than 20 cigarettes per day, were excluded.
All volunteers were examined on two consecutive days,
each after 12-h overnight fast and controlled diet and ac-
tivity for 7 days. Participants had a diet consisting of 50%
carbohydrates, 30% lipids, and 20% proteins, and vigorous
physical exercise was prohibited. On day 1, we performed
anthropometric measurements and an oral glucose toler-
ance test (OGTT), and on day 2, we performed a euglyce-
mic hyperinsulinemic clamp.
Anthropometric measurements
For all participants, we measured height to the nearest
0.5 cm, and weight in light clothes to the nearest 0.1 kg,
and calculated the body mass index (BMI) as weight in
kg/height2 in m2. Individuals were categorized as lean
(BMI < 25 kg/m2), overweight (BMI: 25–29.9 kg/m2) or
obese (BMI ≥ 30 kg/m2). We measured waist and hip cir-
cumference to the nearest 0.5 cm and calculated thewaist-to-hip ratio as well as waist-to-height ratio (WHtR).
Total fat mass, fat-free mass, and percent fat were mea-
sured by dual energy X-ray absorptiometry (DEXA) with
an absorptiometer (Hologic QDR-1000/W, Wilmington,
MA, USA) with Whole Body V5.73 software (n = 19),
or by bioimpedance (TANITA BC 420 MA, TANITA
Corporation 1-14-2 Maeno-cho, Tabashi-ku, Tokyo-
Japan) (n = 68).
Blood pressure was the mean of two measurements
performed at least three minutes apart, in the right arm
with the subject sited after a 15-min rest with an Omron
recorder (manufacturer references).
Fasting measurements
Oral glucose tolerance test
After a 12 h overnight fast, each participant underwent a
75-gram OGTT over 120 minutes. We collected whole
blood samples from an antecubital vein at 0, 30, and
120 min for the determination of blood glucose, and
serum insulin and the evaluation of glucose tolerance
according to World Health Organization Criteria (WHO
1998 criteria) [9], and early phase insulin secretory
response.
Euglycemic hyperinsulinemic clamp
Whole-body insulin sensitivity was evaluated with a 120-
minute euglycemic hyperinsulinemic clamp technique
[4]. After a 12-h overnight fast, at 8 am, a priming dose
of insulin infusion (Actrapid 100 IU/ml; Novo Nordisk,
Gentofte, Denmark) was administrated during the initial
10 minutes to acutely raise plasma insulin to the desired
level, where it was maintained by a continuous insulin in-
fusion at a rate of 80 mU/m2 body surface area per minute.
Blood glucose was clamped at 100 mg/dl (5.5 mmol/l) for
100 minutes by infusing 20% glucose at variable rates ac-
cording to blood glucose measurements performed at
5-min intervals (mean coefficient of variation of blood
glucose was <5%). The mean value for the period from 80
to 100 min was used to calculate the rates of whole body
glucose uptake. In the fasting state and at 80, 90, and
100 min, arterialized blood samples for the measurement
of plasma insulin were performed.
Biochemical assays
We performed all assays twice using the same batch of
kits in each case. Glucose was measured by the glucose
oxidase method, and we used immunoradiometric assays
(Bi-insulin IRMA [Bio-Rad, Marnes la Coquette, France]
to measure insulin. The intra-assay coefficient of vari-
ation was 1.8-3.8% and the inter-assay coefficient of vari-
ation was 2.6-8.0% for insulin. Serum total cholesterol,
high-density lipoprotein (HDL)-cholesterol and triglyce-
rides were measured by means of standard enzymatic
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was calculated using Friedwald’s formula [10].
Calculations of clamp-derived and surrogate indices of
insulin sensitivity
Insulin mediated glucose uptake (M value) was calcu-
lated from the glucose infusion rate during the final
20 min of the glucose clamp as the rate of exogenous
glucose infusion divided by the steady-state clamp insu-
lin concentration, after accounting for differences between
individuals in glucose space (by dividing the average group
steady-state glucose by the individual steady state glucose),
and expressed in mg/min/kg of body fat-free mass [4].
Calculations of fasting-derived indices were made using
the mean of two fasting glucose and insulin concentra-
tions before the start of the euglycemic clamp. The fasting
glucose to insulin ratio (Glucose/Insulin ratio), fasting
insulin resistance index (FIRI = fasting glucose × fasting
insulin/25) [11], the Homeostasis Model Assessment
(HOMA) for insulin resistance (HOMA-IR) [12,13], and
the quantitative insulin sensitivity check index (QUICKI)
[14] were calculated according to established methods.
Given that HOMA-IR and FIRI assess insulin resist-
ance as opposed to sensitivity, negative correlations
with euglycemic clamp measure of insulin sensitivity
would be expected.
Statistical analysis
Data are presented as mean (standard deviation, SD) for
continuous variables and as count and percentage for
categorical variables. We compared groups (BMI and
gender) using the Kruskal-Wallis test for continuous var-
iables, and assessed the heterogeneity across gender and
BMI subgroups through interaction tests. Continuous
associations between indices of insulin sensitivity was
assessed graphically with the use of correlation matrix,
applying the Box-Cox [15] power transformations to im-
prove the shape of the associations; then the “Covariance
Estimation for Multivariate t Distribution” [16] methods
was used to derived the correlation coefficients, while mi-
nimising the potential effects of outliers. The Steiger t test
was used to compare correlation coefficients among indi-
ces of insulin sensitivity. Regression coefficients to indicate
the size of the association of each of the indices with
euglycemic clamp was derived from robust multiple linear
regressions model that included each of the indices of
interest, waist circumference and sex as independent vari-
ables. Agreement was explored by examining the pro-
portion of subjects correctly classified by surrogate indices
of insulin sensitivity, within sex-specific thirds of clamp-
derived measure of insulin sensitivity as the reference.
This was supplemented by a formal statistical testing
using the kappa test to compare the distribution of partici-
pants across increasing thirds of QUICKI and glucose/insulin ratio, or decreasing thirds of age, BMI, waist cir-
cumference, WHtR, fasting insulin HOMA-IR and FIRI,
vs. increasing third of clamp derived insulin sensitivity.
The 95% confidence interval around kappa estimates was
from two-sided bootstrap methods, based on 1000 replica-
tions. Analyses were carried out using SPSS version 17.0
for Windows (SPSS Inc., Chicago, IL) and R statistical
software version 2.13.0 [13-04-2011], (The R Foundation
for Statistical Computing, Vienna, Austria). The signifi-
cance level was set at 0.05.
Results
Characteristics of the study population
The mean age (SD) was 34.6 (11.4) years and the mean
BMI was 27.6 (6.5) kg/m2. Table 1 shows the general
characteristics of the 87 study participants, across sex-
specific BMI categories. In both men and women, there
were significant differences in percent fat, waist circum-
ference, hip circumference, WHtR and total-cholesterol
across BMI categories, with always significant linear
trends. Systolic and diastolic blood pressures, two-hour
glucose and fasting insulin levels were significantly dif-
ferent in men (waist-to-hip ratio in women) across BMI
categories, again, with significant linear trends, except
for systolic blood pressure. In both genders, no signifi-
cant differences across categories of BMI were noted for
age, triglycerides, and cholesterol (HDL and LDL) levels.
There was evidence of heterogeneity by sex and across
BMI categories for waist-to-hip ratio (p = 0.04 for inter-
action) fasting and 2-hour glucose (both p ≤ 0.05), and
marginally for fasting insulin (p = 0.06), but not for
other characteristics (Table 1).
Insulin sensitivity across obesity categories
A total of 79 participants (47 men) had complete data
on all variables of interest. Table 1 shows insulin sensi-
tivity levels from various indices across BMI categories.
The M-value was low in obese men and women, with
significant differences across categories of BMI among
men but not among women, with however no evidence
of interaction (p = 0.27). Fasting plasma insulin, FIRI,
HOMA-IR were highest in obese and lowest in lean men
with significant differences across BMI categories, and in
linear fashions (all p ≤ 0.01 for linear trends); whereas
among women, these were highest in overweight and
lowest among lean, with no significant difference or lin-
ear trends across BMI categories (all p ≥ 0.34); resulting
in significant heterogeneity across sex and BMI catego-
ries (all p ≤ 0.06 for interaction, Table 1). The glucose/in-
sulin ratio was highest among lean men, without any
trend in women (p =0.69 for linearity). The QUICKI
index was lowest in obese men and women, and highest
among lean men and women, with however, significant
difference across BMI categories only in men (p =0.01),
Table 1 Characteristics of the subjects by sex and BMI categories
Men Women p gender
and BMI
interaction
Lean Overweight Obese p Kruskal Wallis p linearity Lean Overweight Obese p Kruskal Wallis p linearity
N 23 18 10 14 9 13
Age (years) 33.1 ± 11.4 36.9 ± 9.3 38.3 ± 9.7 0.23 0.15 31.3 ± 12.9 35.3 ± 16.0 34.2 ± 10.7 0.70 0.56 0.91
BMI ( kg/m2) 22.1 ± 1.4 27.7 ± 1.7 35.3 ± 7.4 <0.001 <0.001 23.0 ± 1.4 27.7 ± 1.5 36.3 ± 5.9 <0.001 <0.001 0.86
Percent fat (%) 14.2 ± 3.6 23.2 ± 6.3 33.6 ± 9.6 <0.001 <0.001 26.6 ± 6.0 32.5 ± 8.0 40.8 ± 5.3 <0.001 <0.001 0.28
Waist circumference (cm) 76.0 ± 4.5 92.8 ± 8.4 109.0 ± 12.8 <0.001 <0.001 78.0 ± 6.7 85.4 ± 7.7 102.6 ± 11.4 <0.001 <0.001 0.09
Hip circumference (cm) 87.1 ± 5.9 97.2 ± 6.1 117.1 ± 15.1 <0.001 <0.001 92.0 ± 9.1 106.9 ± 9.7 119.8 ± 13.3 <0.001 <0.001 0.59
Waist-to-hip ratio 0.89 ± 0.03 0.93 ± 0.04 0.92 ± 0.05 0.12 0.10 0.85 ± 0.06 0.80 ± 0.04 0.88 ± 0.08 0.04 0.40 0.04
Waist-to-height ratio 0.44 ± 0.03 0.53 ± 0.05 0.63 ± 0.09 <0.001 <0.001 0.48 ± 0.05 0.52 ± 0.04 0.63 ± 0.07 <0.001 <0.001 0.10
Systolic blood pressure (mmHg) 122 ± 20 131 ± 21 129 ± 10 0.04 0.22 123 ± 22 117 ± 17 125 ± 6 0.29 0.91 0.34
Diastolic blood pressure (mmHg) 72 ± 9 76 ± 11 84 ± 6 0.006 0.002 75 ± 9 71 ± 6 77 ± 5 0.09 0.47 0.11
Total cholesterol (mg/L) 160 ± 43 210 ± 63 275 ± 45 0.002 <0.001 154 ± 61 182 ± 77 235 ± 55 0.02 0.009 0.67
Triglycerides (mg/L) 50 ± 17 57 ± 20 71 ± 47 0.42 0.17 54 ± 14 47 ± 15 71 ± 43 0.22 0.19 0.80
HDL cholesterol (mg/L) 48 ± 18 63 ± 21 70 ± 32 0.37 0.07 47 ± 20 39 ± 11 58 ± 23 0.10 0.22 0.37
LDL cholesterol (mg/L) 102 ± 40 136 ± 54 191 ± 80 0.02 0.006 96 ± 48 133 ± 81 163 ± 64 0.07 0.03 0.82
Fasting glucose (mmol/L) 4.56 ± 0.58 4.42 ± 0.55 4.93 ± 0.56 0.14 0.21 4.46 ± 0.50 4.85 ± 0.70 4.56 ± 043 0.20 0.61 0.04
2 h glucose (mmol/L) 5.46 ± 1.24 5.26 ± 1.00 8.17 ± 3.40 0.002 0.003 6.36 ± 1.21 6.67 ± 1.68 7.02 ± 1.14 0.48 0.25 0.05
Fasting insulin (mU/L) 4.66 ± 2.56 5.71 ± 4.39 8.95 ± 3.60 0.01 0.007 6.72 ± 2.69 9.56 ± 5.94 7.38 ± 3.26 0.44 0.59 0.06
Euglycaemic clamp
M unadjusted (mg.min−1.kg−1) 10.0 ± 2.7 7.5 ± 2.4 5.2 ± 1.8 <0.001 <0.001 8.4 ± 2.2 7.6 ± 2.8 6.1 ± 1.7 0.02 0.01 0.13
M adjusted to lean mass (mg.min−1.kg−1) 11.6 ± 2.9 9.8 ± 3.3 7.8 ± 2.9 0.004 0.001 11.5 ± 2.7 11.1 ± 3.4 10.4 ± 3.1 0.70 0.35 0.27
Fasting indices
Plasma insulin (mUI/mL) 4.7 ± 2.6 5.7 ± 4.4 8.9 ± 3.6 0.01 0.007 6.7 ± 2.7 9.6 ± 5.9 7.4 ± 3.3 0.44 0.59 0.06
Glucose/Insulin ratio (mmol/mUI) 25.5 ± 18.7 21.6 ± 13.3 11.6 ± 4.9 0.03 0.07 15.7 ± 12.0 13.6 ± 12.1 14.0 ± 6.8 0.50 0.69 0.30
HOMA-IR 0.95 ± 0.57 1.11 ± 0.89 2.00 ± 0.93 0.009 0.004 1.33 ± 0.56 2.08 ± 1.32 1.53 ± 0.65 0.34 0.47 0.02
FIRI 0.85 ± 0.51 1.01 ± 0.80 1.80 ± 0.84 0.009 0.004 1.20 ± 0.50 1.88 ± 1.19 1.37 ± 0.58 0.34 0.47 0.02
QUICKI 0.30 ± 0.15 0.19 ± 0.10 0.11 ± 0.03 0.01 0.10 0.15 ± 0.08 0.13 ± 0.08 0.13 ± 0.03 0.37 0.46 0.32
BMI: body mass index; HDL: high density lipoprotein cholesterol; LDL: low density lipoprotein cholesterol; HOMA-IR: Homeostasis Model Assessment for insulin resistance; FIRI: fasting insulin resistance index; QUICKI:
quantitative insulin sensitivity check index.
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interaction).
Correlation between fasting indices, clinical surrogates,
and clamp measures
The correlation matrix of fasting indices and clinical sur-
rogates of insulin sensitivity with clamp-derived index isFigure 1 Correlation between clamp-derived insulin sensitivity index
sensitivity overall and in men and women. Plots are based on the Box-C
the Box-Cox transformed M value (y-axis). Across figure panels, the filled cir
each figure panel, the superimposed curves are the linear regression lines d
overall (solid line) and for men (dotted lines) and women (broken lines). Th
are also shown.described in Figure 1. In the overall sample, correlation
coefficients (95% confidence interval) for fasting indices
vs. clamp-derived index were −0.27 (−0.47 to −0.05) for
fasting insulin, −0.30 (−0.49 to −0.09) for HOMA-IR,
0.29 (0.07 to 0.48) for QUICKI, −0.30 (−0.49 to −0.09)
for FIRI and 0.23 (0.01 to 0.43) for glucose/insulin ratio.
In analyses stratified by sex, the pattern was similar, with(M value), and fasting indices and clinical surrogates of insulin
ox transformed values of insulin sensitivity of interest (x-axis) against
cles are always for men and the point-up triangles for women. For
epicting the continuous association of indices of interest with M value
e accompanying correlation coefficient and 95% confidence intervals
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p > 0.60 for men vs. women comparisons). In the overall
sample, correlations of fasting indices with clamp-derived
index appeared to be significantly different for fasting
insulin vs. QUICKI (p = 0.01) and glucose/insulin ratio
(p = 0.03); HOMA-IR vs. QUICKI (p = 0.008) and glu-
cose/insulin ratio (p = 0.02); QUICKI vs. FIRI (p = 0.008);
and FIRI vs. glucose/insulin ratio (p = 0.02). The pattern
was similar in men and women.
In the overall sample, correlation coefficients (95%
confidence interval) clinical surrogates vs. clamp-derived
index were −0.08 (−0.30 to 0.14) for age, −0.38 (−0.55
to −0.17) for BMI, −0.43 (−0.60 to −0.23) for waist cir-
cumference and −0.38 (−0.56 to −0.18) for WHtR. There
was a trend toward stronger correlation in men than in
women (Figure 1 and Table 2). The correlations of clamp
with BMI, WC and WHtR were stronger than those with
QUICKI, FIRI and glucose/insulin ratio (all p ≤ 0.0004),
and not appreciably different to those with fasting insulin
and HOMA-IR.
The best fitting multivariable model containing sex
and each of the clinical surrogates was achieved with
waist circumference (R2 = 0.202), in predicting clamp-
derived index (Table 2). Adding any of the other clinical
surrogates did not improve the fit of the model. The ef-
fect of each of the fasting indices on clamp-derived value
was only marginal in multivariable models (Table 2).
Altogether, each index, sex and waist circumference
in the same model accounted for about 25 to 27% of
the variability of clamp-derived measure of insulin sen-
sitivity. Adding the interaction terms of indices with
sex did not improve the fit of the models, while re-
placing WC with either BMI or WHtR resulted in less
performing models. Across competing models (with
each of the indices), WC was always the most signifi-
cant and consistent determinant of clamp-derived index
(Table 2).Classification agreement
The proportion of participants correctly ranked in cross-
classification across thirds of clamp-derived and fast-
ing insulin sensitivity indices and clinical surrogates is
shown in Table 3. This proportion ranged from 27%
to 51% overall, 25% to 68% in men, and 25% to 47%
in women based on fasting indices. Significant kappa
statistic were observed in the overall sample and in men
for QUICKI vs. Clamp [kappa 0.24 (95% CI: 0.09-0.42)
and 0.27 (0.05-0.46)], and for glucose/insulin ratio vs.
clamp [0.26 (0.09-0.42) and 0.30 (0.08-0.51)]; but not
in women, or for other fasting indices (Table 3). The
best performing clinical surrogate was BMI [kappa
0.22 (0.05-0.38) in the overall sample and 0.36 (0.14-
0.58) in men].Discussion
This study aimed to validate a wide-range of fasting indi-
ces of insulin sensitivity against hyperinsulinemic eugly-
cemic clamp among non-diabetic sub-Saharan Africans.
We found that, although fasting indices of insulin sensi-
tivity were strongly correlated with each other, they only
displayed weak associations with clamp-derived measure
of insulin sensitive, and consistently among men and
women. These associations were further attenuated after
adjustment for clinical markers of adiposity, which ap-
peared to be significant determinants of insulin sensitiv-
ity in this population. However, accounting for the effect
of adiposity (via waist circumference), sex and fasting in-
dices explained just about 25% of the variability of insu-
lin sensitivity in our sample. Among participants ranked
by thirds of fasting indices, less than half fall within
the corresponding category based on thirds of clamp-
derived measure. Similar results were obtained when
using clinical surrogates of insulin sensitivity. Our re-
sults are of importance given the rapid ongoing changes
in physical activity and nutritional behaviors, resulting in
increasing insulin resistance and consequential escalating
rates of diabetes and obesity in SSA. Addressing these
challenges would require larger-scale studies of T2DM or
obesity, in which the use of examined indices may prove
beneficial.
The relatively low levels of correlations between indi-
ces and clamp measures may be the result of a higher
basal insulin secretion in people of African ancestry [17],
which may have clouded the relationship between these
indices and clamp-derived measure. Although a direct
comparison of our findings with what would be obtained
in a Caucasian population is not possible, our results
after adjusting for sex and adiposity are similar to those
reported by Pisprasert et al. [7] who found similar coef-
ficients of correlation between clamp-derived insulin
sensitivity index and HOMA-IR (0.266 vs. 0.290) as well
as QUICKI (0.263 vs. 0.265). In overweight African-
American premenopausal women, Alvarez et al. [6] re-
ported similar coefficients of correlation between insulin
sensitivity index and Glucose/Insulin ratio while the coef-
ficient was slightly higher for fasting insulin (0.261 vs.
0.308) and HOMA-IR (0.266 vs. 0.309), and lower for
QUICKI (0.263 vs. 0.249). In all groups assessed in our
study, fasting insulin had comparable correlations to those
observed with the more complex indices of insulin resist-
ance (HOMA-IR, QUICKI or FIRI) with clamp insulin
sensitivity. Thus, HOMA-IR, QUICKI, and FIRI may not
necessarily provide better estimation of insulin sensitivity
than that obtained from fasting insulin alone in individuals
of SSA origin.
Very few studies have examined surrogate indices
against clamp-derived measures in population from SSA.
Existing studies have mainly been from South Africa and
Table 2 Regression coefficients from multiple robust linear models for the prediction of clamp-derived index by fasting insulin sensitivity indices accounting
for the potential effect of sex and adiposity
BMI Waist WHtR BMI & WC Fasting insulin HOMA-IR QUICKI FIRI Glucose/insulin
β p β p β p β p β p β p β p β p β p
Insuline sensitivity index - - - - - - - - −1.472 0.01 −1.454 0.01 0.331 0.01 −1.454 0.01 1.761 0.03
Sex (female) 1.277 0.10 0.726 0.27 1.368 0.05 0.873 0.31 1.156 0.09 1.171 0.07 1.162 0.08 1.171 0.07 1.093 0.13
BMI −200.3 0.0003 - - - - 74.94 0.56 - - - - - - - - - -
Waist - - −8.964 <0.0001 - - 6.130 0.30 −7.985 0.0002 −7.606 0.0004 −7.805 0.0002 −7.606 0.0004 −8.470 0.0002
WHtR −8.1465 0.0002 - - - - - - - - - -
R2 0.179 0.202 0.177 0.200 0.261 0.266 0.263 0.266 0.248
BMI: body mass index; WHtR: waist-to-height ratio; β: standard regression coefficient; R2: coefficient of determination.
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Table 3 Proportion of subjects correctly classified by each index using clamp-derived M thirds as reference insulin sensitivity categories
Men Women All subjects
Insulin sensitivity
category
Low Medium High Total Kappa (95% CI) Low Medium High Total Kappa (95% CI) Low Medium High Total Kappa (95% CI)
Using clamp as
reference
N = 15 N = 16 N = 16 N = 47 N = 10 N = 11 N = 11 N = 32 N = 25 N = 27 N = 27 N = 79
Fasting plasma
insulin
20% 44% 25% 14/47 −0.05 (−0.25 to 0.14) 30% 36% 9% 8/32 −0.13 (−0.33 to 0.10) 24% 41% 18% 22/79 −0.08 (−0.22 to 0.08)
Glucose/Insulin
ratio
53% 56% 50% 25/47 0.30 (0.08 to 0.51) 50% 45% 45% 15/32 0.20 (−0.08 to 0.47) 52% 52% 48% 40/79 0.26 (0.09 to 0.42)
HOMA-IR 20% 37% 19% 12/47 −0.12 (−0.30 to 0.06) 20% 45% 18% 9/32 −0.08 (−0.31 to 0.15) 20% 41% 18% 21/79 −0.10 (−0.24 to 0.04)
FIRI 20% 37% 19% 12/47 −0.12 (−0.30 to 0.08) 20% 45% 18% 9/32 −0.08 (−0.30 to 0.16) 20% 41% 18% 21/79 −0.10 (−0.24 to 0.04)
QUICKI 53% 50% 50% 24/47 0.27 (0.05 to 0.46) 50% 36% 54% 15/32 0.20 (−0.04 to 0.47) 52% 44% 52% 39/79 0.24 (0.09 to 0.42)
Age 27% 9% 56% 15/47 −0.02 (−0.22 to 0.18) 10% 45% 27% 9/32 −0.08 (−0.32 to 0.16) 20% 26% 44% 24/79 −0.04 (−0.19 to 0.11)
BMI 53% 56% 62% 27/47 0.36 (0.14 to 0.58) 50% 27% 27% 11/32 0.01 (−0.23 to 0.25) 52% 44% 48% 38/79 0.22 (0.05 to 0.38)
Waist 53% 31% 56% 21/47 0.20 (−0.02 to 0.40) 50% 27% 18% 10/32 −0.03 (−0.26 to 0.22) 52% 30% 41% 32/79 0.11 (−0.06 to 0.27)
WHtR 53% 31% 62% 25/47 0.23 (0.01 to 0.43) 50% 36% 18% 11/32 0.01 (−0.22 to 0.25) 52% 33% 44% 34/79 0.14 (−0.02 to 0.31)
HOMA-IR: Homeostasis Model Assessment for insulin resistance; FIRI: fasting insulin resistance index; QUICKI: quantitative insulin sensitivity check index;
BMI: body mass index; WHtR: waist-to-height ratio.
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contrary to our investigation that comprehensively ex-
amined a wide range of indices. Ntyintyane et al. [18],
reported significant correlations between clamp-derived
insulin sensitivity and log HOMA-IR (r = −0.34) and
QUICKI (r = 0.41) among Black South Africans; which
in major ways were similar to those from our study.
However, their study was based on a smaller and more
heterogeneous group of participants including people
with coronary heart disease and or diabetes mellitus
[18]. Furthermore, they did not adjust clamp-derived
M-values for lean body mass, and used lower insulin in-
fusion rates (40 mU/m2/min), which may have resulted
in incomplete suppression of hepatic glucose produc-
tion (HGP) in participants with high BMI.
Our study has some limitations. Firstly, the study cir-
cumstances may not fully mimic real-life situation in the
sense that participants were under controlled conditions
before testing. Secondly, although we included more par-
ticipants than any previous study from SSA, our sample
size may still be small to uncover some significant associa-
tions. However, performing clamp studies in larger sample
is logistically challenging in any setting. Thirdly, although
we used a high-rate insulin infusion, in the absence of
concomitant use of radiolabeled glucose tracer during the
clamp studies, we are unable to confirm that we achieved
total suppression of hepatic glucose production. Fourthly,
we used two different methods (absorptiometry and bio-
impedance) to measure fat body mass. This approach
could possible induce differential measurement error, with
possible, by likely marginal effect on the relationship of
fasting indices and clamp-derived measures [19]. Lastly,
we excluded heavy smokers (>20 cigarettes per day) from
our sample. We made this choice because of uncertainties
surrounding the association between smoking and insulin
resistance from studies in Caucasians [20-22]. There have
been suggestions that smoking 24 cigarettes per day in-
creases energy expenditure by about 10% [23], which in
turn could be associated with a lower body mass index, a
key determinant of insulin resistance.
The strengths of our study relate primarily to our reliance
on robust methods including: 1) the use of the reference
method for estimating insulin sensitivity (hyperinsulinemic
euglycemic clamp); the use of a systematic sequential- as
opposed to a random approach to OGTT and the clamp
studies; 3) the use of multiple and robust statistical ap-
proaches to assess the validity of surrogate indices. Fur-
thermore, our cohort included a wide range of insulin
sensitivity/BMI, as BMI is known to influence the relation-
ship between surrogate indices and direct measurements of
insulin sensitivity [24]. In the absence of established cut-off
to diagnosed insulin resistance in this population, we pur-
posefully refrained from assessing the predictive utility of
indices based on arbitrary cut-offs derived from our sample.Conclusions
In conclusion, fasting indices for insulin sensitivity are
very modest determinants of clamp-derived measure
of insulin sensitivity among non-diabetic sub-Saharan
Africans. Furthermore, these indices appear not to per-
form better than common clinical measures of adiposity,
nor to add significant predictive information to knowledge
from non-invasive clinical measure in predicting insulin
sensitivity. More research efforts are needed to identify in
this setting to identify affordable fasting indicators which,
singly or in combination may improve the accuracy of in-
sulin sensitivity prediction. Predictive research in other
settings has demonstrated the usefulness of routine clin-
ical parameters in predicting the occurrence of diabetes
mellitus or cardiovascular diseases, which are all long-
term consequence of insulin resistance [25,26]. Adapting
knowledge from those studies to the African setting will
significantly improve the prevention and control of insulin
resistance related status, without necessarily measuring in-
sulin sensitivity, which at present appear to be unreliable
using advocated fasting estimators.
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